<DOC>
	<DOCNO>NCT00338182</DOCNO>
	<brief_summary>The primary purpose protocol investigate safety tolerability AZD1152 give continuous 48-hour infusion every 14 day 2-hour infusion 2 consecutive day every 14 day patient advance solid malignancy .</brief_summary>
	<brief_title>AZD1152 Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Histological cytological confirmation solid , malignant tumour At least one measurable nonmeasurable site disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Participation investigational drug study within 21 day prior therapy recovered effect investigational study drug Recent major surgery within 4 week prior entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid tumor</keyword>
</DOC>